Durvalumab after definitive chemoradiotherapy in locally advanced unresectable Non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)

Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer death worldwide. At the time of initial diagnosis approximately 30% of patients have locally advanced disease (stage III) which is often unresectable. (1,2,3) Chemoradiotherapy (CRT) including platinum-based doublet chemotherapy used to be the standard of care for patients with a good performance status and unresectable stage III NSCLC. (4,5) Although CRT is performed with curative intent, patient prognosis has been poor with median progression-free survival (PFS) of approximately 8 months and 5-year overall survival (OS) of 15 to 30%.

Source: Lung Cancer - October 21, 2020 Category: Cancer & Oncology Authors: Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, J ürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph Source Type: research